Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
View Patent ↗The present invention relates to a bioresorbable scaffold for a vascular stent comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone. The nitric oxide agonist is a statin or a HMG CoA reductase inhibitor. The nitric oxide agonist may be coated on the polymer, incorporated within the polymer or chemically bonded to the polymer. The invention also relates to a method for treating atherothrombosclerotic occlusive disease of an artery comprising implanting into the artery a stent with a bioresorbable scaffold comprising a nitric oxide agonist and a polymer comprising a lactide, a glycolide and a lactone, wherein the nitric oxide agonist is exuded from or released from the bioresorbable scaffold.
1. A vascular stent comprising a bioresorbable scaffold comprising a polymer wherein the polymer comprises statin and one or more monomers selected from the group consisting of lactide, glycolide, and epsilon-caprolactone wherein the statin is incorporated as repeating monomeric units into the body of the polymer.
2. The vascular stent of claim 1 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
3. The vascular stent of claim 2 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
4. The vascular stent of claim 1 , wherein the polymer is selected from the group consisting of polylactide statin, polyglycolide statin, polyepsilon caprolactone statin, polylactide-glycolide statin, polylactide-epsilon caprolactone statin, polyglycolide-epsilon caprolactone statin, polylactide glycolide-epsilon-caprolactone statin and mixtures thereof.
5. The vascular stent of claim 4 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
6. The vascular stent of claim 5 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
7. The vascular stent of claim 4 , wherein the polymer is polylactide statin.
8. The vascular stent of claim 7 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
9. The vascular stent of claim 8 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
10. The vascular stent of claim 4 , wherein the polymer is polyglycolide statin.
11. The vascular stent of claim 10 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
12. The vascular stent of claim 11 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
13. The vascular stent of claim 4 , wherein the polymer is polyepsilon caprolactone statin.
14. The vascular stent of claim 13 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
15. The vascular stent of claim 14 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
16. The vascular stent of claim 4 , wherein the polymer is polylactide glycolide statin.
17. The vascular stent of claim 16 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
18. The vascular stent of claim 17 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
19. The vascular stent of claim 4 , wherein the polymer is polylactide epsilon caprolactone statin.
20. The vascular stent of claim 19 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
21. The vascular stent of claim 20 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
22. The vascular stent of claim 4 , wherein the polymer is polyglycolide epsilon caprolactone statin.
23. The vascular stent of claim 22 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
24. The vascular stent of claim 23 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.
25. The vascular stent of claim 4 , wherein the polymer is polylactide glycolide-epsilon-caprolactone statin.
26. The vascular stent of claim 25 , wherein the statin is selected from the group consisting of velostatin, dihydrocompactin, carvastatin, bevastatin, cefvastatin, glenvastatin, simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, compactin and mixtures thereof.
27. The vascular stent of claim 26 , wherein the statin is selected from the group consisting of simvastatin, lovastatin, atorvastatin, pravastatin, cerivastatin, rosuvastatin, pitavastatin, fluvastatin, mevastatin, dalvastatin, and compactin.